Isis Pharmaceuticals, Inc. Form 10K - page 37

37
Jurisdiction PatentNo. Title Expiration DescriptionofClaims
UnitedStates ......... 7,407,943 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2021 Methods of inhibiting expressionof apoB,
decreasing serum cholesterol, decreasing
lipoprotein levels, decreasing serum
triglycerides in a humanwith an antisense
compound12 to30nucleotide in length and
100% complementary tohuman apoB
wherein the compound is not a ribozyme.
Australia................ 2002-326481 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2021 An isolatedoligonucleotide compound12 to
30nucleobases in length100%
complementary to at least a 12-nucleobase
portionof a nucleic acidmolecule having
nucleotides 151-12820of SEQ ID3 (apoB)
which is not a ribozyme anduse of such
compound in therapy
Japan ..................... 4471650 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2021 Use of an antisense oligonucleotide 12 to 30
nucleobases in length and100%
complementary to human apoBhavingone or
moremodifications and inhibiting expression
of apoBby at least 90% in primary
hepatocyteswhen present at a concentration
of 300nM for preparationof amedicament
for decreasing serum cholesterol, and
decreasing lipoprotein levels in a human
UnitedStates ......... 7,511,131 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2025 Antisense sequence and compositionof
matter ofKYNAMRO
Europe ................... EP1569695 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2023 Antisense sequence and compositionof
matter ofKYNAMRO
Europe ................... EP2336318 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2023 Antisense sequence and compositionof
matter ofKYNAMRO
India ...................... 219847 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2023 Antisense sequence and compositionof
matter ofKYNAMRO
Australia................ 2003294281 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2023 Antisense sequence and compositionof
matter ofKYNAMRO
SouthAfrica .......... 2005/03690 ANTISENSEMODULATION
OFAPOLIPOPROTEINB
EXPRESSION
2023 Antisense sequence and compositionof
matter ofKYNAMRO
Custirsen
Issuedpatent claims have beenobtained from an application jointly filedby Isis andOncoGenex toprotect the specific
chemical composition of custirsen in theUnitedStates. The issuedU.S. claims shouldprotect custirsen fromgeneric competition in
theUnitedStates until at least 2021. The table below lists theU.S. issuedpatent:
Jurisdiction PatentNo. Title Expiration DescriptionofClaims
UnitedStates ....... 6,900,187 TRPM-2ANTISENSETHERAPY
USINGANOLIOGNUCLEOTIDE
HAVING2’-O-(2-
METHOXY)ETHYL
MODIFICATIONS
2021 Antisense sequence and compositionof
custirsen